BIOGEN INC. Impairment of Intangible Assets (Excluding Goodwill)
BIOGEN INC. (BIIB) reported Impairment of Intangible Assets (Excluding Goodwill) of $7.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2026-02-06
- BIOGEN INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2021-06-30 was $0.00.
- BIOGEN INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2021-03-31 was $0.00.
- BIOGEN INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2020-12-31 was $209.70M, a 2.87% decline year-over-year.
- BIOGEN INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2020-09-30 was $0.00.
- BIOGEN INC. impairment of intangible assets (excluding goodwill) for fiscal 2025 was $7.90M, a 86.88% decline from fiscal 2024.
- BIOGEN INC. impairment of intangible assets (excluding goodwill) for fiscal 2024 was $60.20M.
- BIOGEN INC. impairment of intangible assets (excluding goodwill) for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- BIOGEN INC. impairment of intangible assets (excluding goodwill) for fiscal 2022 was $119.60M, a 80.99% decline from fiscal 2021.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $7.90M 10-K · filed 2026-02-06 | |||
| 2024-12-31 | $60.20M 10-K · filed 2026-02-06 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-06 | |||
| 2022-12-31 | $119.60M 10-K · filed 2025-02-12 | |||
| 2021-12-31 | $629.30M 10-K · filed 2024-02-14 | |||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-22 | $0.00 10-Q · filed 2021-07-22 | $209.70M derived: sum of 3 quarters · filed 2023-02-15 | $209.70M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $0.00 10-Q · filed 2021-04-22 | $209.70M derived: sum of 2 quarters · filed 2023-02-15 | $209.70M derived: sum of 3 quarters · filed 2023-02-15 | $209.70M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $209.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $209.70M derived: sum of 2 quarters · filed 2023-02-15 | $209.70M derived: sum of 3 quarters · filed 2023-02-15 | $209.70M 10-K · filed 2023-02-15 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-21 | $0.00 derived: sum of 2 quarters · filed 2021-07-22 | $0.00 10-Q · filed 2020-10-21 | $215.90M derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-06-30 | $0.00 10-Q · filed 2021-07-22 | $0.00 10-Q · filed 2021-07-22 | $215.90M derived: sum of 3 quarters · filed 2022-02-03 | $215.90M derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-03-31 | $0.00 10-Q · filed 2021-04-22 | $215.90M derived: sum of 2 quarters · filed 2022-02-03 | $215.90M derived: sum of 3 quarters · filed 2022-02-03 | $215.90M derived: sum of 4 quarters · filed 2022-02-03 |
| 2019-12-31 | $215.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03 | $215.90M derived: sum of 2 quarters · filed 2022-02-03 | $215.90M derived: sum of 3 quarters · filed 2022-02-03 | $215.90M 10-K · filed 2022-02-03 |
| 2019-09-30 | $0.00 10-Q · filed 2020-10-21 | $0.00 derived: sum of 2 quarters · filed 2020-10-21 | $0.00 10-Q · filed 2020-10-21 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-07-22 | $0.00 10-Q · filed 2020-07-22 | ||
| 2019-03-31 | $0.00 10-Q · filed 2020-04-23 | |||
| 2018-12-31 | $366.10M 10-K · filed 2021-02-03 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | $50.90M 10-K · filed 2015-02-04 | ||
| 2014-09-30 | $50.90M 10-Q · filed 2014-10-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |